Regencell Bioscience (NASDAQ:RGC) Shares Up 9.2% – Still a Buy?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) were up 9.2% during mid-day trading on Thursday . The company traded as high as $18.38 and last traded at $18.36. Approximately 220,037 shares changed hands during trading, a decline of 97% from the average daily volume of 7,450,103 shares. The stock had previously closed at $16.81.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Regencell Bioscience Trading Up 4.7%

The business has a fifty day moving average of $15.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in shares of Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after purchasing an additional 384,250 shares during the period. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience in the 2nd quarter worth approximately $1,701,000. BNP Paribas Financial Markets acquired a new stake in shares of Regencell Bioscience during the 2nd quarter valued at $768,000. XTX Topco Ltd acquired a new stake in shares of Regencell Bioscience during the 3rd quarter valued at $598,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Regencell Bioscience during the 2nd quarter valued at $222,000. Hedge funds and other institutional investors own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.